GLP-1 Muscle Loss: Genetics, Biomarkers & Body Composition

Last reviewed: May 22, 2026

Last updated: May 22, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

GLP-1 medications primarily reduce fat mass, but muscle loss can occur—particularly during rapid weight loss or with inadequate protein intake. Research shows that 20–30% of weight loss on GLP-1s may include lean muscle if resistance training and protein consumption are insufficient, though this varies significantly by individual metabolic factors.

Body composition outcomes depend on genetics, lifestyle, and baseline health status. PlexusDx emphasizes precision wellness by combining genetic insights into your metabolic pathways with clinical guidance, helping you make informed decisions about whether compounded GLP-1 therapy aligns with your body composition goals before starting treatment.

How GLP-1 Medications Affect Fat vs. Muscle Tissue

GLP-1 agonists work by increasing satiety and reducing caloric intake, which creates a caloric deficit that preferentially mobilizes fat stores. The mechanism itself is not selective for muscle; however, when overall calories drop without adequate protein and resistance exercise, your body may use amino acids for energy.

Clinical studies indicate that GLP-1 users who maintain consistent strength training and consume 1.6–2.2 grams of protein per kilogram of body weight retain significantly more lean muscle than those who do not. This suggests that muscle preservation is largely within your control through lifestyle modifications during treatment.

Genetic and Metabolic Factors Influencing Muscle Preservation on GLP-1s

Your genetic makeup influences how efficiently you build and maintain muscle, process nutrients, and regulate appetite. Specific variants in genes like MC4R and FTO affect baseline metabolic rate and protein metabolism, potentially influencing muscle loss risk during weight loss. The Precision Peptide Genetic Test evaluates key variants in peptide and metabolic pathways to provide personalized context for your response pattern.

Genetic Factor	Role in Muscle Metabolism	Clinical Relevance on GLP-1s
MC4R rs17782313	Regulates energy expenditure and lean mass	May affect baseline muscle loss tendency; high-risk variants warrant stronger protein/exercise emphasis
FTO rs9939609	Influences metabolic rate and fat distribution	Can affect how rapidly you lose weight; faster loss may increase muscle catabolism risk
GIPR rs1800437	Involved in glucose metabolism and energy balance	May correlate with lean mass preservation patterns during caloric deficit
GLP1R rs6923761	Affects GLP-1 signaling sensitivity and appetite suppression	Influences individual variation in weight loss trajectory and muscle retention likelihood

Protein Intake, Resistance Training, and Muscle Preservation Strategy

The single most modifiable factor in preserving muscle on GLP-1 therapy is adequate protein intake combined with consistent resistance training. Aim for 1.6–2.2 grams of protein per kilogram of ideal body weight daily, distributed across three to four meals, to maximize muscle protein synthesis during a caloric deficit.

Resistance training two to four times weekly activates mTOR and other anabolic pathways that signal your body to preserve muscle tissue. Studies show that patients combining GLP-1 therapy with structured resistance training lose 80–90% fat relative to total weight loss, compared to 50–70% without exercise. Your provider can help tailor a nutrition and exercise plan aligned with your individual metabolic profile.

Who Is at Higher Risk for Muscle Loss and When to Involve Your Provider

Patients over 65, those with pre-existing sarcopenia, individuals losing weight rapidly (more than 1–2 pounds weekly), and those with sedentary baseline activity levels face elevated muscle loss risk. Additionally, patients with low baseline protein intake or insufficient micronutrient status (vitamin D, B12, iron) may experience accelerated lean mass decline.

Before starting any GLP-1 medication, discuss body composition goals with your provider. Baseline measurements—such as DXA scan, bioelectrical impedance, or DEXA—can establish your lean muscle percentage and guide personalized protein and exercise targets. Your provider can also assess whether genetic predispositions (revealed by precision testing) warrant preventive strategies like earlier nutritional counseling or supervised resistance training.

How PlexusDx Supports a More Personalized Approach

The Precision Peptide Genetic Test evaluates variants in MC4R, FTO, GIPR, and GLP1R pathways to provide context about your baseline metabolic rate, muscle protein synthesis capacity, and individual response patterns. This information may help you and your provider anticipate muscle preservation challenges and adjust protein, exercise, and supplementation strategies proactively before starting compounded semaglutide or tirzepatide therapy.

Genetic predispositions do not determine exact medication response or muscle loss magnitude—they reveal tendencies within peptide and metabolic pathways. For example, certain FTO variants correlate with faster metabolic adaptation during weight loss, while MC4R variants may influence baseline energy expenditure and lean mass distribution. These insights should be interpreted with your qualified healthcare provider as one component of a comprehensive assessment.

Understanding your genetic landscape may support a more informed conversation with your provider about which compounded GLP-1 option (semaglutide injection, tirzepatide injection, oral formulations) aligns with your body composition goals, and what protein, exercise, and monitoring protocols could optimize your outcome. This precision approach is central to PlexusDx's philosophy of personalized weight management.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month, or $298 standalone) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Oral starts at $279/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.